17899-49-9 Usage
Uses
Used in Pharmaceutical Industry:
5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is used as a potential pharmaceutical compound for [application reason]. Its unique structure, which includes a thiazole ring, a pyridine ring, and an ethyl group, may contribute to its potential therapeutic properties and applications in drug development.
Used in Agrochemical Industry:
5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE is used as a potential agrochemical compound for [application reason]. 5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE's distinctive molecular structure may offer advantages in the development of new agrochemical products, such as pesticides or herbicides, that could improve agricultural practices and crop protection.
(Note: The specific application reasons for the pharmaceutical and agrochemical industries are not provided in the materials. Therefore, they are left as placeholders to be filled in with accurate information once it becomes available through further research and analysis.)
Check Digit Verification of cas no
The CAS Registry Mumber 17899-49-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,8,9 and 9 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 17899-49:
(7*1)+(6*7)+(5*8)+(4*9)+(3*9)+(2*4)+(1*9)=169
169 % 10 = 9
So 17899-49-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H13N3S/c1-2-11-4-3-6-7(5-11)12-8(9)10-6/h2-5H2,1H3,(H2,9,10)/p+1
17899-49-9Relevant academic research and scientific papers
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation
Wang, Zhengyu,Shi, Xiaofan,Zhang, Huan,Yu, Liang,Cheng, Yanhua,Zhang, Hefeng,Zhang, Huibin,Zhou, Jinpei,Chen, Jing,Shen, Xu,Duan, Wenhu
, p. 128 - 152 (2017/08/10)
Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.
